Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a, Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies

NCT04504708 is registered in ClinicalTrials.gov with Hangzhou Zenshine Pharmaceuticals Co., Ltd. as lead sponsor.

NCT NCT04504708
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04504708 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a, Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies
Lead sponsor
Hangzhou Zenshine Pharmaceuticals Co., Ltd.
Phase
Phase 1/2
Overall status
Terminated
Start date
February 17, 2021
Completion date
July 8, 2022
Enrollment
6 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia, non-hodgkin lymphoma, small lymphocytic lymphoma